A detailed history of China Universal Asset Management Co., Ltd. transactions in Genmab A/S stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 8,064 shares of GMAB stock, worth $166,037. This represents 0.02% of its overall portfolio holdings.

Number of Shares
8,064
Previous 4,927 63.67%
Holding current value
$166,037
Previous $123,000 59.35%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$23.84 - $28.48 $74,786 - $89,341
3,137 Added 63.67%
8,064 $196,000
Q2 2024

Jul 19, 2024

SELL
$25.13 - $30.27 $77,827 - $93,746
-3,097 Reduced 38.6%
4,927 $123,000
Q1 2024

Apr 29, 2024

BUY
$26.43 - $32.77 $84,020 - $104,175
3,179 Added 65.61%
8,024 $240,000
Q4 2023

May 21, 2024

SELL
$27.94 - $35.44 $88,821 - $112,663
-3,179 Reduced 39.62%
4,845 $154,000
Q4 2023

Jan 23, 2024

BUY
$27.94 - $35.44 $105,333 - $133,608
3,770 Added 350.7%
4,845 $154,000
Q3 2023

May 21, 2024

BUY
$35.27 - $42.24 $17,564 - $21,035
498 Added 86.31%
1,075 $37,000
Q3 2023

Oct 30, 2023

BUY
$35.27 - $42.24 $17,564 - $21,035
498 Added 86.31%
1,075 $38,000
Q2 2023

May 21, 2024

SELL
$37.4 - $42.94 $2,057 - $2,361
-55 Reduced 8.7%
577 $21,000
Q2 2023

Jul 27, 2023

SELL
$37.4 - $42.94 $2,057 - $2,361
-55 Reduced 8.7%
577 $22,000
Q1 2023

May 21, 2024

BUY
$34.88 - $43.22 $6,906 - $8,557
198 Added 45.62%
632 $23,000
Q1 2023

Apr 27, 2023

BUY
$34.88 - $43.22 $6,906 - $8,557
198 Added 45.62%
632 $24,000
Q4 2022

May 21, 2024

SELL
$33.8 - $47.06 $256,541 - $357,185
-7,590 Reduced 94.59%
434 $18,000
Q4 2022

Jan 31, 2023

BUY
$33.8 - $47.06 $2,737 - $3,811
81 Added 22.95%
434 $18,000
Q3 2022

Oct 21, 2022

BUY
$31.52 - $373.61 $11,126 - $131,884
353 New
353 $11,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.